Global Multiple System Atrophy (MSA) Therapeutics Market Continues Upward Trajectory, Projected to Reach US$ 211.1 Million by 2033 at a 4.4% CAGR

Multiple System Atrophy (MSA) Therapeutics Market
Multiple System Atrophy (MSA) Therapeutics Market

The global Multiple System Atrophy (MSA) therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 4.4%, with a current valuation of US$ 137.3 million by 2023. Healthcare technology advancements are expected to drive the market to US$ 211.1 million by 2033.

Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16285

Key Takeaways:

  • The MSA therapeutics market is expected to reach US$211.1 million by 2033, driven by a CAGR of 4.4%.
  • Limited treatment options for MSA highlight the significant need for novel therapies.
  • Technological advancements in gene therapy and other areas hold promise for the future of MSA treatment.
  • Growing disease awareness is leading to earlier diagnosis and a greater demand for effective treatments.

Competitive Landscape:

Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.

The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.

Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.

  • In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced new milestones in potential therapeutic approaches for ALS.
  • In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, and infectious and autoimmune diseases.

Explore Our Methodology Framework:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16285

Key Companies Profiled:

  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
  • Merck & Co.
  • Neuropore Therapies Inc
  • Newron Pharmaceuticals SpA
  • ProMIS Neurosciences Inc
  • Stealth BioTherapeutics Corp
  • Chelsea Therapeutics International, Ltd.

Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey:

Multiple System Atrophy (MSA) Therapeutics Market by Type:

  • Parkinsonian
  • Cerebellar

Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:

  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Single Photon Emission Computed Tomography (SPECT)
  • Tilt Table Test
  • Others

Multiple System Atrophy (MSA) Therapeutics Market by RegionP:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16285

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Pancreatic Cancer Industry Expected to Reach US$7.5 Billion by 2033, Driven by Steady Growth at 13.5% CAGR | FMI Analysis

Global Pancreatic Cancer Industry
Global Pancreatic Cancer Industry

The Global Pancreatic Cancer Industry is poised for significant growth, according to a groundbreaking new analysis from Future Market Insights Inc. (FMI), a leading healthcare research firm. The market is expected to reach a valuation of approximately US$2,125.57 million by the end of 2023. Looking ahead, the market is projected to climb at a robust Compound Annual Growth Rate (CAGR) of 13.5%, reaching an impressive US$7,541.09 million by 2033.

Among the most common types of cancer in the world, pancreatic cancer is a serious illness with far-reaching consequences. The fact that HPV is the seventh most common cause of cancer-related deaths worldwide, according to alarming data, emphasizes how urgent it is to address this pressing healthcare issue.

The analysis further highlights a notable upward trend in the prevalence of pancreatic cancer, particularly in the Western world. Of concern is the rise in cases of pancreatic adenocarcinoma within developed regions. Lifestyle factors, including alcohol consumption and obesity, are believed to be substantial contributors to this worrisome trend.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16183

Why Choose Future Market Insights

  • Serving domestic and international clients 24/7
  • Prompt and efficient customer service
  • Data collected from reliable primary and secondary sources
  • Highly trained and experienced team of research analysts
  • Seamless delivery of tailor-made market research reports

Global Pancreatic Cancer Industry: Segmentation

Valuable information covered in FMI’s Global Pancreatic Cancer Industry report has been segregated into key segments and sub-segments.

By Treatment Type:

Grab Your Discount Now Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16183

By Cancer Type:

  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Research Laboratories
  • Others

Global Pancreatic Cancer Industry: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Global Pancreatic Cancer Industry. Competitive information detailed in the Pancreatic Cancer market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Global Pancreatic Cancer Industry report.

Key players covered in the Global Pancreatic Cancer Industry report include:

  1. Pfizer Inc.
  2. Novartis AG
  3. Eli Lily and Company
  4. Bristol Myers Squibb Company
  5. Zydus Cadila
  6. Myriad Genetics Inc.
  7. F-Hoffmann-La Roche Ltd.
  8. PharmaCyte Biotech Inc.
  9. Teva Pharmaceutical Industries Ltd.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16183

Important Questions Answered in the Global Pancreatic Cancer Industry Report

  • Which end-user remains the top revenue contributor in different regional markets?
  • At what rate has the global Global Pancreatic Cancer Industry been expanding during the forecast period?
  • How will the global Pancreatic Cancer market look like by the end of the forecast period?
  • What innovative strategies are adopted by Global Pancreatic Cancer Industry players to stay ahead of the pack?
  • What are the restraints affecting the growth of the global Pancreatic Cancer market?

Key Offerings of the Report

  • Growth Drivers and Opportunities: Comprehensive analysis of growth-driving factors and opportunities for market players in different regional markets
  • Recent Trends and Forecasts: Detailed assessment of the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
  • Segmental Analysis: Extensive analysis of each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
  • Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with the necessary information to make critical decisions
  • Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Global Pancreatic Cancer Industry

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Non-Small Cell Lung Carcinoma Industry Expected to Reach US$21.4 Billion by 2033, Driven by 10% CAGR Growth | FMI

Global Non-Small Cell Lung Carcinoma Industry
Global Non-Small Cell Lung Carcinoma Industry

The Global Non-Small Cell Lung Carcinoma Industry is on a trajectory for significant growth, fueled by a robust Compound Annual Growth Rate (CAGR) of 10% projected from 2023 to 2033. According to market analysts, the market is expected to reach an impressive US$8.25 billion by 2023, and a staggering US$21.40 billion by 2033. This growth highlights the increasing focus on the diagnosis and treatment of this prevalent form of lung cancer.

Carefully considered insights obtained by FMI, the leading authority on healthcare insights and data, serve as the foundation for this revolutionary change. Utilizing the most recent data obtained from significant global producers of pharmaceuticals and medical equipment, FMI offers a comprehensive study of the Non-Small Cell Lung Carcinoma (NSCLC) market, offering unmatched insight into the future of the sector.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16180

Over the past decade, the healthcare sector has expanded remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancements in technology have created impressive scope within the medical sector for diagnostics and therapeutics.

The report offers extensive data sets validating key trends impacting growth in the Non-Small Cell Lung Carcinoma (NSCLC) Industry. It offers insights into strategies adopted by the key players and addresses the concerns that will challenge the growth of the Non-Small Cell Lung Carcinoma (NSCLC) Industry. With our extensive research and information about the past, current, and future market scenario, the Non-Small Cell Lung Carcinoma (NSCLC) market report will help and identify the concerns, for a smooth sail of small & medium as well as large enterprises.

Competitive Analysis

By Prominent Global Non-Small Cell Lung Carcinoma Industry Players

Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.

With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects, and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Non-Small Cell Lung Carcinoma (NSCLC) market

Critical Questions Answered in the Report

  1. What are ongoing trends that will shape the market growth curve for the global Non-Small Cell Lung Carcinoma (NSCLC) Industry?
  2. What are the drivers and challenges affecting the Non-Small Cell Lung Carcinoma (NSCLC) Industry demand?
  3. What are the recent technological advancements in the Non-Small Cell Lung Carcinoma (NSCLC) Industry?
  4. What are key trends and opportunities that will prevail in the revenue growth of Non-Small Cell Lung Carcinoma (NSCLC) Industry players?
  5. How will evolving regulatory policies impact market growth?
  6. What is the impact of Covid-19 on the Non-Small Cell Lung Carcinoma (NSCLC) Industry?

Global Non-Small Cell Lung Carcinoma Industry: Segmentation

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa

Detailed analysis of the geographical region and country-wise insights are offered in the latest Non-Small Cell Lung Carcinoma (NSCLC) Industry report with established market players as well as incumbents in the region.

Key Segments Profiled in the Global Non-Small Cell Lung Carcinoma Industry Survey

Type:

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors

Treatment:

  • Chemotherapy
  • Targeted Therapy
    • Bevacizumab (Avastin)
    • Nectiumumbab (Portrazza)
    • Ramucirumab (Cyramza)
  • Immunotherapy
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentrig)
  • Others

End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Comprehensive analysis of the regional markets offers exclusive insights into the market performance across geographies along with relevant graphs, figures, and a list of tables.

Tap into Comprehensive Segmented Information – Purchase Now!
https://www.futuremarketinsights.com/checkout/16180

Why Future Market Insights?

  • Comprehensive analysis of evolving purchase patterns across different geographies
  • Detailed insights of market segments and sub-segments for historical as well as forecast period
  • A competitive analysis of prominent players and emerging players in the Non-Small Cell Lung Carcinoma (NSCLC) Industry
  • Detailed information about the product innovation, mergers, and acquisitions lined up in upcoming years
  • Groundbreaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Alpha-1 Antitrypsin Deficiency Market for Spectacular Growth, Projected to Reach US$ 10 Billion by 2033 at a 12.8% CAGR

Alpha-1 Antitrypsin Deficiency Market
Alpha-1 Antitrypsin Deficiency Market

The global  Alpha-1 Antitrypsin Deficiency (AATD) treatments market is anticipated to reach US$ 10 billion by 2033, growing at a compound annual growth rate of 12.8% from its projected US$ 3 billion market value in 2023. The increasing prevalence of respiratory ailments is one of the main factors propelling market expansion. In addition, the growing use of augmentation therapy is driving market growth.

The purpose of augmentation therapy is to increase the concentration of AAT in the respiratory tracts of patients by isolating the protein from healthy donors’ blood plasma. This treatment reduces the number of exacerbations, speeds up recovery, and decreases the emphysema’s growth. These components contribute to its increasing popularity among medical experts and patients.

It is also expected that research and development (R&D) investments will have a big impact on the sector. Many firms are working to create a portfolio that could alter the course of business by using their own competencies and expanding those through strategic alliances, R&D, and possible licensing, merger, and acquisition operations.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16288

Key Takeaways from the Market Study

  • The global alpha-1 antitrypsin insufficiency market is expected to develop at a 12.8% CAGR by 2033, according to FMI.
  • The global market for Alpha-1 Antitrypsin Deficiency is anticipated to be over US$ 3 billion.
  • The global market for Alpha-1 Antitrypsin Deficiency is expected to be around US$ 10 billion.
  • According to Future Market Insights, Asia Pacific will grow at a CAGR of 12% between 2023 and 2033.
  • North America is expected to grow at a 12.7% CAGR between 2023 and 2033.
  • Europe is expected to grow at a 12.3% CAGR between 2023 and 2033.

“Within North America, the United States has dominated the market. The rising number of government funding, developments in gene therapy research and development, and the rising penetration of target illnesses are the primary drivers driving the Alpha-1 Antitrypsin Deficiency market expansion,” says an analyst at FMI

Market Competition

To address the present patient pool’s requests and counter the therapeutic market’s unmet needs, drug developers are increasingly moving their focus to alpha-1 antitrypsin deficiency (AATD).

Many novel medicines are being developed by several businesses, including ARO-AAT (Arrowhead Pharmaceutical), Alvelestat (Mereo Biopharma), and Inhaled AAT (Kamada).

ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously given drug that lowers hepatic synthesis of the mutant AAT protein by knocking down the alpha-1 antitrypsin (AAT) gene transcript. The business is now undertaking Phase II clinical studies to assess the drug’s safety, tolerability, and pharmacodynamic impact in AATD patients.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16288

Key players in the Alpha-1 Antitrypsin Deficiency (A1ATD) market are:

  • Pfizer
  • Baxter
  • AstraZeneca
  • Grifols
  • Teva Pharmaceutical Industries
  • BoehringerIngelheim
  • Kamada Ltd
  • GlaxoSmithKline
  •  CSL Behring
  • LFB Biomedicaments

Recent Developments:

Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced in October 2022 that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for a total estimated value of US$ 22 million. This award ensures that such products will continue to be sold in Canada. In November 2021, Kamada purchased four commercial pharmaceuticals that have been licensed by Health Canada and the United States Food and Drug Administration (FDA).

Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey

By Product Type:

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy

By Application:

  • Hospitals
  • Specialty Clinics
  • Pharmacies

Extensive Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16288

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Intratumoral Cancer Therapies Industry Set to Explode: Poised to Reach US$552 Billion by 2033 at 10% CAGR | FMI Analysis

Global Intratumoral Cancer Therapies Industry
Global Intratumoral Cancer Therapies Industry

The Global Intratumoral Cancer Therapies Industry is poised for a remarkable transformation, with a projected market value of US$552.36 billion by 2033 according to a recent report by Future Market Insights (FMI). This translates to a phenomenal Compound Annual Growth Rate (CAGR) of 10% expected throughout the 2023-2033 forecast period. This significant growth represents a substantial leap from the 2023 market value of US$212.96 billion.

Favorable Regulatory Landscape Paves the Way for Growth

The exceptional growth trajectory of the intratumoral cancer therapies market can be attributed primarily to a supportive regulatory environment for innovative cancer treatments. This follows a period of steady growth, with the market expanding at a CAGR of 7% from 2017 to 2022. The upcoming decade is expected to witness a significant acceleration in market growth fueled by these factors.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16153

In terms of market share and revenue, the North American market is predicted to be the most lucrative market during the forecast period with a revenue share of 40%. The region’s growth is driven by the presence of various biotechnology and medical device firms. For instance, in March 2020, Johnson and Johnson received the US FDA Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Key Takeaways from the Global Intratumoral Cancer Therapies Industry Study

  • From 2017-2022, the Intratumoral Cancer Therapies market grew at a CAGR of 7%.
  • The global Intratumoral Cancer Therapies market is expected to grow with a 10% CAGR during 2023-2033.
  • As of 2033, the Intratumoral Cancer Therapies market is expected to reach US$ 552.36 Billion.
  • The checkpoint inhibitors segment is poised to register the highest growth rate through 2033.
  • North America is expected to possess a 40% market share for the Intratumoral Cancer Therapies market in North America.
  • The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
  • By application, lung cancer is estimated to account for the largest share of the market.

“Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions to reduce the incidence level.” says an FMI analyst

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16153

Global Intratumoral Cancer Therapies Industry Competition

Key players in the Intratumoral Cancer Therapies market are Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson, and Eli Lily Company, F.

  • Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. The drug business stated in a statement that it has released the medicine in the US market through a partner who has acquired permission from the US Food and Drug Administration (USFDA). The business claims that its medicine is medically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib Intravenous is used to treat cancers such as myeloma and mantle cell lymphoma.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Intratumoral Cancer Therapies market, presenting a historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights based on technology (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines), application (Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Others), end-users (Hospitals, Cancer Research Centres, Clinics) & region.

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16153

Key Segments Profiled in the Global Intratumoral Cancer Therapies Industry Survey

Technology:

Application:

End-users:

  • Hospitals
  • Cancer Research Centres
  • Clinics

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Vessel Sealing Devices Industry Set for Explosive Growth, Reaching US$3.9 Billion by 2033 at 9% CAGR | FMI Analysis

Global Vessel Sealing Devices Industry
Global Vessel Sealing Devices Industry

The Global Vessel Sealing Devices Industry is on track for a remarkable surge, with a projected valuation of US$3.9 billion by 2033. This signifies a significant increase from its estimated value of US$1.65 billion in 2023. The market is poised for a new era of expansion, fueled by a robust Compound Annual Growth Rate (CAGR) of 9% anticipated throughout the forecast period.

Vascular-sealing instruments have become essential instruments in many medical fields; they are effective in laparoscopic, neck, and axillary dissection procedures, among other procedures. The vessel-sealing market has become a dominant force in the healthcare industry thanks to their adaptability and reliable performance, which have propelled them to the forefront of medical technology.

As these cutting-edge devices continue to outperform traditional methods in clinical applications, their influence is expected to steadily rise, shaping the future of surgical interventions. The vessel-sealing market’s upward trajectory is further fueled by the continuous evolution of surgical devices and a notable uptick in FDA approvals for vessel-sealing technologies. These regulatory milestones, combined with technological advancements, are anticipated to propel market expansion throughout the forecast period.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16109

With fewer blood loss complications and less operating time, surgeons have improved safety and efficiency. Technological advancements in surgical devices and FDA guidelines regarding vessel-sealing devices are likely to drive the growth of the market.

Surgical procedures, product developments, and minimally invasive surgery are a few of the main drivers of this market.

Key Takeaways from the Global Vessel Sealing Devices Industry:

  • The vessel-sealing devices market is expected to increase at a notable CAGR of 9%
  • North America is a prominent market for vessel-sealing devices and is estimated to expand at a CAGR of 4.5% in the forecast period.
  • The United States is projected to account for 75% of the North American vessel-sealing devices market.
  • Hospitals and specialty clinics are expected to account for a prominent share of the market and rise at a CAGR of 4.86%.

Global Vessel Sealing Devices Industry Competitive Landscape

Manufacturers of vessel-sealing devices implement a variety of strategies to meet the needs of domestic and international customers as part of their competitive strategy. To satisfy the needs of domestic and international customers, companies such as Medtronic PLC maintain a steady emphasis on research and development to minimize risk during operations. Furthermore, to gain an advantage over their competition, key players continue to develop products through acquisition, partnerships, and innovation.

Key companies in the Global Vessel Sealing Devices Industry include 

  1. Medtronic PLC,
  2. B Braun Melsungen AG, and
  3. Erbe Medical India Pvt. Ltd,
  4. Olympus Corporation,
  5. Ethicon US LLC (Johnson & Johnson),
  6. Boston Scientific Corporation,
  7. BOWA-electronic GmbH & Co. KG,
  8. OmniGuide Holdings Inc.,
  9. CONMED Corporation, Bolder Surgical Holdings Inc,

Recent Developments in the Global Vessel Sealing Devices Industry

  • Olympus Corporation, a Japan-based manufacturer, offers Thunderbeat instrument lineups for endoscopic and open surgery. The device uses ultrasonic energy for fast and precise dissection.
  • In September 2022, Olympus expanded its global footprint with an investment of US$ 34 million in Coimbra, Portugal.
  • Ethicon’s Enseal X1 Curved Jaw Tissue Sealer was released in June 2021. This product is used for gynecological, thoracic, bariatric, and colorectal procedures.
  • Hologic Inc., a medical technology company, acquired Bolder Surgical, a developer and manufacturer of energy vessel sealing surgical devices, in October 2021 for US$ 160 million, to broaden their surgical portfolio.

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/16109

Segments Covered in the Global Vessel Sealing Devices Industry Analysis

By Application

  • General Surgery
  • Laparoscopic Surgery

By End User

By Region

  • North America
  • Latin America
  • Europe
  • The Middle East and Africa
  • East Asia

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Chronic Wound Care Market Continues Upward Trajectory, Projected to Reach US$ 25,042.5 Million at a 3.8% CAGR

Chronic Wound Care Market
Chronic Wound Care Market

The global chronic wound care market is anticipated to grow at a CAGR of 3.8%. It is anticipated that by 2033, the market value will have grown from US$ 17,272.4 million in 2023 to US$ 25,042.5 million. The market for chronic wound care was estimated to be worth US$ 16,689.3 million in 2022, and in 2023, it is projected to increase at a rate of 3.5% year over year.

As a result of increased research and development by numerous governmental and non-governmental entities, new, creative items should hit the market. According to a Frontiers in Physics research, new smart bandages have been developed that allow clinicians to speak with patients without having to touch the wound.

In addition, scientists from the Indian Institute of Science have created magnetic nanofiber bandages that provide a non-invasive method of treating skin cancer. Researchers at IISc have created a bandage that is created by electrospinning a unique blend of nanoparticles. It has been demonstrated that for the best possible wound care, real-time monitoring of wound parameters at the wound site using a range of sensing modalities—including chemical and physical sensors—is crucial. A substantial amount of work has been put into developing technologies in recent years to track several parameters that affect the healing process of wounds, including pH, temperature, pressure, and infection status. To aid in wound diagnosis and treatment, advanced wound therapies have been created, such as local and on-demand drug administration.

Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16277

The advancement of technology and innovative 3D techniques, along with trackers and apps, will allow consumers to monitor the healing process of their finger wounds. For instance, Heriot-Watt University researchers developed tiny sensors that track wound healing and speed using a bandage under a bandage. There have been many studies on wound biology, but little is known about the physicality’s that contribute to wound healing, especially at the microscale, where advancement occurs at sub-hair widths. Crichton writes that few studies have actually been conducted on wounds.  

Key Takeaways from the Market Study 

  • The global market size for chronic wound care is estimated to reach US$ 15.98 Billion by 2023.
  • According to the forecast, the market is expected to grow by 7% between 2023 and 2033, reaching a total of US$ 31.46 billion by 2033.
  • Across all wound dressing categories in 2023, advanced wound dressings accounted for 54% of the total market value.
  • Chronic wound care in North America expanded with a market share of 33% in 2022.
  • According to forecasts, by 2023 the diabetic ulcer market will account for 38% of the total market value.

“As diabetic ulcers become more prevalent and new drugs and devices are approved, artificial intelligence and technology are expected to play a significant role in growing sensor-based bandages.” comments a Future Market Insights analyst.

Competitive Landscape 

Research and the development of innovative diagnostic techniques are expected to be the focus of many companies in the near future, resulting in the expansion of their product lines, the acquisition of other companies, and the merger of their businesses.

  • Healthium Medtech, based in Bengaluru, has introduced its new wound dressing portfolio Theruptor Novo to manage chronic wound care such as diabetic foot ulcers and leg ulcers. Healthium expands its portfolio of advanced wound dressing products with Theruptor Novo. Approximately 25% of diabetics will develop a foot ulcer during their lifetime. As a result of complications caused by untreated diabetic foot ulcers, almost 1 lakh amputations have been registered in India today. In addition to being painful and expensive, foot ulcers require a lot of treatment.
  • In an era when complex chronic wound care are on the rise, while access to wound care nurse specialists is becoming more challenging, HARTMAN USA and Corstrata announce their partnership to support home health and other in-home providers. Clinical expertise and evidence-based treatment protocols are essential to integrate advanced wound dressings with a successful wound care program. BerryDunn’s National Healthcare at Home Best Practices and Future Insights Study, published in recent months by top-50 accounting firm BerryDunn, indicates that wound-certified specialists are on staff at all of the top 10% of home health agencies with positive financial surpluses.

 Key Companies Profiled:

  • Paracrine, Inc.
  • Oneness Biotech
  • Biotissue
  • Polarity TE
  • MediWound
  • Anterogen Co., Ltd.
  • TR Therapeutics
  • RHEACELL GmbH & Co.KG
  • Smith & Nephew
  • Kaken Pharmaceutical

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16277

Key Segments Profiled in the Chronic Wound Care Market Industry Survey

Type:

  • Diabetic Ulcers
  • Pressure Ulcers
  • Venous Ulcers
  • Other Chronic Wounds

Product:

  • Advanced Wound Dressings
  • Wound Care Therapy
  • Active Therapy
  • Others

End User:

  • Hospital and Wound Care Centers
  • Homecare Settings
  • Others

Explore Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16277

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry Projected to Reach US$2.7 Billion by 2033, Driven by Steady Growth at 5.6% CAGR | FMI

Global Catheter-Related Bloodstream Infection Treatment
Global Catheter-Related Bloodstream Infection Treatment

The Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry is poised for significant growth, with a projected valuation of US$2,668.6 million by 2033. This represents a robust Compound Annual Growth Rate (CAGR) of 5.6% anticipated during the forecast period (2023-2033). The market’s current strength is evident from its estimated value of US$1,466.9 million in 2022.

Although the COVID-19 pandemic affected various end-user industries, it also created pressure on the healthcare industry. As more people suffered from various ailments during the pandemic, the demand for catheters increased. As more patients were exposed to the use of catheters, the rate of bloodstream infections increased too.

Furthermore, technological advancements play a crucial role in fueling the market growth. For instance, miniaturized catheters and the introduction of antimicrobial catheters are expected to reduce catheter-associated infections Although major players are innovating, launching, and introducing safer catheters, the limited expansion of the same is contributing to the market for catheter-related bloodstream infusions.

Request Sample Report + Related Graphs & Charts
https://www.futuremarketinsights.com/reports/sample/rep-gb-16130

Key Takeaways from the Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry Study

  • By distribution channel, hospital pharmacies are expected to possess a 40% market share for the catheter-related bloodstream infections market in 2023.
  • By drug class, antimicrobial catheters are expected to possess a 35% market share for catheter-related bloodstream infections in 2023.
  • North America is expected to possess a 35% market share for the catheter-related bloodstream infection market in 2023.
  • Asia Pacific is expected to possess a 30% market share for the catheter-related bloodstream infection market in 2023.

“Rise in prevalence of diseases that require catheter are increasing the number of patients suffering from catheter-related bloodstream infections. This, in turn, is supporting the growth of the market.” states a FMI analyst

Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry Competitive Landscape

Key players in the catheter-related bloodstream infection are Xellia Pharmaceuticals Ltd, Pfizer, Glenmark Pharmaceuticals Ltd, Fresenius Medical Care, CorMedix, TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd, Merck Sharp & Dohme Corp

  • In August 2021, Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
  • In February 2020, CorMedix, Inc. announced that Neutrolin received a grant from the U.S. Food and Drug Administration for the prevention of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.

Intravascular catheter-associated bloodstream infection (ICABSI) is an infection that occurs when bacteria or other microorganisms enter the bloodstream through a catheter. Catheters are medical devices that are inserted into the body to deliver fluids, medications, or nutrition. They are commonly used in hospitals, long-term care facilities, and in the home for patients who require ongoing medical treatment.

Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry Key Companies Profiled: 

  • Xellia Pharmaceuticals Ltd.
  • Pfizer
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Medical Care
  • CorMedix
  • TauroPhar GmbH
  • Geistlich Pharma
  • Citus Pharmaceuticals
  • AstraZeneca Pharma India Ltd.
  • Merck Sharp & Dohme Corp

Key Segments Profiled in the Global Catheter-Related Bloodstream Infection (CRBSI) Treatment Industry Survey

Drug Class:

Pathogens:

  • Contaminated Catheter Hub
  • Contaminated Infusate
  • Skin Insertion
  • Hematogenous

Source of Infection:

  • Aureus
  • Aeruginsa
  • CONS
  • Baumanii
  • Coli
  • Pnemoniae
  • Candida sp

Route of Administration:

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

For more Report Customization, connect with us at
https://www.futuremarketinsights.com/customization-available/rep-gb-16130

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Personal Care Packaging Market Set to Reach US$ 68.0 Billion by 2034, Fueled by Rising Consumer Demand

The personal care packaging market is a dynamic sector within the broader packaging industry that caters specifically to products in the personal care and beauty industry. Personal care products encompass a wide range, including skincare, haircare, cosmetics, fragrances, and toiletries. Packaging for these products plays a crucial role in brand identity, product protection, and consumer convenience.

The personal care packaging market is poised for significant growth, with a projected market value of US$ 43.8 billion by the year 2024. Anticipating further expansion, the market is expected to reach a valuation of US$ 68.0 billion by 2034. This trajectory reflects a robust Compound Annual Growth Rate (CAGR) of 4.5% throughout the forecast period spanning from 2024 to 2034.

The escalating market value signifies the increasing importance placed on packaging within the personal care industry. As consumers demand not only effective and appealing personal care products but also sustainable and innovative packaging solutions, the market is witnessing a continuous evolution to meet these expectations. The projected growth underscores the pivotal role that packaging plays in product differentiation, brand identity, and overall consumer experience within the dynamic landscape of the personal care sector.

Get Exclusive Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18460

Market Key Trends

Adherence to strict regulations governing packaging materials, particularly in the realm of personal care items, holds the potential to instigate shifts in packaging methodologies. Ensuring compliance with regulatory standards and prioritizing product safety stand as imperative considerations for participants in the market.

The expanding market for premium and luxury personal care goods has opened avenues for packaging that communicates a sense of refinement and exclusivity. Premium personal care packaging frequently integrates high-quality materials, distinctive designs, and upscale finishes to align with the elevated expectations associated with luxury products.

The integration of intelligent packaging technologies, such as QR codes, RFID tags, or augmented reality, represents a forward-looking approach to personal care packaging. These technologies not only furnish additional information to consumers but also elevate their overall interaction with personal care products, enhancing the user experience.

Market Drivers

A growing awareness among consumers regarding the environmental repercussions of packaging has spurred a heightened emphasis on sustainability. Anticipating this shift in consumer sentiment, businesses within the personal care sector are anticipated to embrace eco-friendly packaging solutions, aligning with market expectations and striving to minimize their environmental impact.

Elevating the appeal of personal care products can be achieved through imaginative and utilitarian packaging designs. Pioneering advancements in packaging materials, configurations, and functionalities present an opportunity for product distinctiveness on store shelves. These innovations not only set products apart but also capture consumer attention, emphasizing the crucial interplay between packaging creativity and consumer engagement.

Request For Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-18460

Market Opportunity

  • Integration of smart packaging technologies, such as radio frequency identification and near field communication, allows for interactive packaging that provides information to consumers, enhances product engagement, and supports supply chain visibility.
  • AR and VR technologies are being used in packaging to create interactive and immersive experiences for consumers. The trend enhances brand engagement and provides a novel way for consumers to explore and understand personal care products.

Key Players

  • Amcor Plc
  • WestRock Company
  • Mondi Group
  • Sonoco Products Company
  • Gerresheimer Ag
  • Albea Services S.A.S
  • HCT Packaging Inc
  • Ampac Holdings LLC
  • Crown Holdings Inc.
  • Ball Corporation

Market Segmentation

By Application:

  • Skin Care
  • Hair Care
  • Make Up
  • Nail Care

By Packaging Format:

  • Bottles
  • Jars
  • Tubes
  • Sachet
  • Stick Packs
  • Pouches
  • Others

By Capacity:

  • Up to 50 ml
  • 51 ml to 100 ml
  • 101 ml to 200 ml
  • Above 200 ml

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia & Pacific
  • East Asia
  • The Middle East & Africa

Buy this Exclusive Report: https://www.futuremarketinsights.com/checkout/18460

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global HER2 Positive Gastric Cancer Market Set to Flourish, Expected to Reach US$1779.8 Million by 2033 with a 3.5% CAGR

HER2 Positive Gastric Cancer Market
HER2 Positive Gastric Cancer Market

The global HER2-positive gastric cancer treatments market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, with a current valuation of US$ 1261.8 million by 2023. Healthcare technology advancements are expected to drive the market to US$1779.8 million by 2033.

The market for gastric cancer that is HER2-positive will likely experience rapid expansion as more people become aware of the symptoms and causes of the illness.The market is expected to develop due to an increase in product releases and approvals, as well as increased business activity in conducting clinical trials to find effective treatments for patients with stomach cancer that is HER2 positive.

For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product, to treat HER-2 positive stomach cancers that have spread. Additionally, it is projected that the market’s growth would be aided by the increasing number of drugs in the pipeline that are gaining special designations.

Reveal Patterns With Your Sample Report Preview:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16232

North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

  • As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
  • From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
  • By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
  • Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
  • China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033

“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16232

Competitive Landscape

  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
  • Hutchison Medipharma
  • LintonPharm
  • Shanghai Henlius Biotech
  • Sanofi
  • Pfizer
  • Novartis AG

Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.

  • In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
  • In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

HER2 Positive Gastric Cancer Market by End-User:

  • Ambulatory surgery centres,
  • Hospitals and Specialty clinics
  • Others

Unlock In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16232

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube